ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 237 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q1 2022. The put-call ratio across all filers is 2.14 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $918,237 | +1.8% | 25,757 | +31.7% | 0.01% | +14.3% |
| Q2 2023 | $901,841 | -3.1% | 19,550 | -15.7% | 0.01% | -12.5% |
| Q1 2023 | $930,480 | -34.7% | 23,204 | -24.5% | 0.01% | -38.5% |
| Q4 2022 | $1,424,648 | +13.5% | 30,750 | +1.5% | 0.01% | +18.2% |
| Q3 2022 | $1,255,000 | -30.8% | 30,309 | -0.3% | 0.01% | -21.4% |
| Q2 2022 | $1,814,000 | -13.8% | 30,399 | +4.9% | 0.01% | +7.7% |
| Q1 2022 | $2,104,000 | -9.1% | 28,984 | +5.3% | 0.01% | +8.3% |
| Q4 2021 | $2,315,000 | +4.0% | 27,524 | +11.5% | 0.01% | -7.7% |
| Q3 2021 | $2,226,000 | -5.8% | 24,679 | -0.4% | 0.01% | -7.1% |
| Q2 2021 | $2,364,000 | -6.7% | 24,788 | +11.4% | 0.01% | -17.6% |
| Q1 2021 | $2,533,000 | -0.4% | 22,245 | +21.0% | 0.02% | +6.2% |
| Q4 2020 | $2,544,000 | -2.9% | 18,379 | -42.3% | 0.02% | -15.8% |
| Q3 2020 | $2,619,000 | -19.3% | 31,865 | -23.2% | 0.02% | -24.0% |
| Q2 2020 | $3,246,000 | +50.3% | 41,493 | -14.6% | 0.02% | +13.6% |
| Q1 2020 | $2,159,000 | -13.0% | 48,601 | -16.4% | 0.02% | +15.8% |
| Q4 2019 | $2,483,000 | +22.3% | 58,140 | +22.5% | 0.02% | +18.8% |
| Q3 2019 | $2,031,000 | -26.7% | 47,468 | +8.8% | 0.02% | -30.4% |
| Q2 2019 | $2,770,000 | -13.0% | 43,629 | -5.0% | 0.02% | -11.5% |
| Q1 2019 | $3,185,000 | +48.3% | 45,925 | -7.0% | 0.03% | +44.4% |
| Q4 2018 | $2,148,000 | -38.5% | 49,401 | +8.0% | 0.02% | -21.7% |
| Q3 2018 | $3,491,000 | -4.0% | 45,725 | -3.4% | 0.02% | -4.2% |
| Q2 2018 | $3,638,000 | +23.8% | 47,330 | -17.9% | 0.02% | +242.9% |
| Q1 2018 | $2,939,000 | +10.9% | 57,647 | +1.0% | 0.01% | +16.7% |
| Q4 2017 | $2,649,000 | -27.9% | 57,102 | -17.2% | 0.01% | -33.3% |
| Q3 2017 | $3,675,000 | +12.9% | 68,994 | +31.7% | 0.01% | 0.0% |
| Q2 2017 | $3,254,000 | +5.0% | 52,405 | +14.6% | 0.01% | +12.5% |
| Q1 2017 | $3,098,000 | -6.7% | 45,721 | -3.2% | 0.01% | -11.1% |
| Q4 2016 | $3,320,000 | -10.3% | 47,217 | -9.5% | 0.01% | -25.0% |
| Q3 2016 | $3,701,000 | +28.7% | 52,177 | -11.2% | 0.01% | +33.3% |
| Q2 2016 | $2,875,000 | -61.0% | 58,774 | -10.6% | 0.01% | -57.1% |
| Q4 2015 | $7,372,000 | +31.8% | 65,713 | +13.1% | 0.02% | +23.5% |
| Q3 2015 | $5,595,000 | +108.9% | 58,091 | +122.1% | 0.02% | +142.9% |
| Q2 2015 | $2,678,000 | -29.4% | 26,159 | -61.0% | 0.01% | -22.2% |
| Q3 2014 | $3,795,000 | – | 67,043 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 727,426 | $25,932,737 | 4.72% |
| RTW INVESTMENTS, LP | 5,405,089 | $192,691,423 | 4.07% |
| First Light Asset Management, LLC | 1,125,032 | $40,107,391 | 3.81% |
| CHI Advisors LLC | 215,000 | $7,664,750 | 3.04% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 250,052 | $8,914,354 | 3.00% |
| SPHERA FUNDS MANAGEMENT LTD. | 259,135 | $9,238,163 | 1.68% |
| Rock Springs Capital Management LP | 1,476,441 | $52,635,122 | 1.41% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 679,459 | $24,222,713 | 1.31% |
| Privium Fund Management B.V. | 115,241 | $4,108,341 | 1.22% |
| SECTOR GAMMA AS | 115,166 | $4,105,668 | 1.05% |